/

AbbVie Inc.

ABBV US

ABBV USAbbVie Inc.

United States Composite

161.72

USD

-0.92

(-0.57%)

2.74EPS Dil.

58.80P/E

285.59BMarket Cap

3.69%Div. Yield

Next Earnings

April 25

Ex-Dividend Date

April 12

Dividend Date

May 15

Held by Insiders

0.12%

Held by Institutions

71.89%

Short % of Float

0.81%

YTD Yield

10.73%

3Y Yield

50.57%

5Y Yield

113.95%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

5,203

5,115

7,191

LT Borrowings

55,812

55,631

52,194

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

1,765

1,766

Market Capitalization

237,771

263,163

273,668

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

28,852

33,224

33,002

Cash, Cash Equivalents & STI

8,766

13,290

12,816

Accounts Receivable, Net

11,491

11,412

11,155

Inventories

4,055

3,981

4,099

Total Current Liabilities

32,239

34,773

37,841

Payables & Accruals

27,036

29,658

30,650

ST Debt

5,203

5,115

7,191

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

11.79%

11.76%

-6.44%

Net Income, GAAP

23.58%

18.17%

-58.91%

Free Cash Flow

22.59%

12.71%

-9.02%

Total Cash Common Dividend

15.58%

13.74%

4.94%

Total Equity

-44.00%

-53.41%

-39.86%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

13,010

13,959

14,342

14,886

56,197

2022

13,538

14,583

14,812

15,121

58,054

2023

12,225

13,865

13,927

14,301

54,318

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

2.01

0.43

1.80

2.28

6.52

2022

2.54

0.52

2.23

1.40

6.68

2023

0.14

1.15

1.01

0.46

2.75

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

1.31

5.23

2022

1.43

1.42

1.41

1.42

5.67

2023

1.50

1.49

5.96

Company Description

CEO: Mr. Richard A. Gonzalez
Full Time Employees: 50,000
Sector: Healthcare
Industry: Drug Manufacturers - General
Address: 1 North Waukegan Road North Chicago IL United States 60064-6400
IPO Date: Jan 2, 2013
Website: www.abbvie.com
Business: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Company News

Tipranks
a month ago
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and AbbVie (ABBV)
Reuters
a month ago
US takes next step in Medicare drug price negotiations with pharma companies
Yahoo
a month ago
US takes next step in Medicare drug price negotiations with pharma companies
Yahoo
a month ago
NEXGEL, Inc. (NASDAQ:NXGL) Q4 2023 Earnings Call Transcript
Reuters
a month ago
Roivant's anti-inflammatory drug succeeds in mid-stage study
FOOL
a month ago
Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation
Yahoo
a month ago
AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks
a month ago
AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks
a month ago
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
Zacks
a month ago
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
Yahoo
a month ago
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
Zacks
a month ago
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Tipranks
a month ago
This Biopharma Stock Outperforms MSTR and SMCI in March 2024
FOOL
a month ago
3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade
Zacks
a month ago
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
Yahoo
a month ago
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
CNBC
a month ago
Here are Thursday's biggest analyst calls: Nvidia, Meta, Tesla, Apple, CyberArk, Grindr, Estee Lauder & more
Yahoo
a month ago
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
Zacks
a month ago
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
Yahoo
a month ago
Long Live the Dividend Kings: 3 Top Picks to Build an Income Portfolio

Company Description

CEO: Mr. Richard A. Gonzalez
Full Time Employees: 50,000
Sector: Healthcare
Industry: Drug Manufacturers - General
Address: 1 North Waukegan Road North Chicago IL United States 60064-6400
IPO Date: Jan 2, 2013
Website: www.abbvie.com
Business: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Company News

Tipranks
a month ago
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and AbbVie (ABBV)
Reuters
a month ago
US takes next step in Medicare drug price negotiations with pharma companies
Yahoo
a month ago
US takes next step in Medicare drug price negotiations with pharma companies
Yahoo
a month ago
NEXGEL, Inc. (NASDAQ:NXGL) Q4 2023 Earnings Call Transcript
Reuters
a month ago
Roivant's anti-inflammatory drug succeeds in mid-stage study
FOOL
a month ago
Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation
Yahoo
a month ago
AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks
a month ago
AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks
a month ago
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
Zacks
a month ago
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
Yahoo
a month ago
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
Zacks
a month ago
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Tipranks
a month ago
This Biopharma Stock Outperforms MSTR and SMCI in March 2024
FOOL
a month ago
3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade
Zacks
a month ago
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
Yahoo
a month ago
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
CNBC
a month ago
Here are Thursday's biggest analyst calls: Nvidia, Meta, Tesla, Apple, CyberArk, Grindr, Estee Lauder & more
Yahoo
a month ago
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
Zacks
a month ago
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
Yahoo
a month ago
Long Live the Dividend Kings: 3 Top Picks to Build an Income Portfolio